KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

Private equity
• Source: Shutterstock

Karo Healthcare will soon have new private-equity owners after EQT agreed a deal to sell the Stockholm, Sweden-based consumer health player to KKR. While financial details were not disclosed, the transaction values Karo at more than €2.5bn ($2.8bn), according to media reports.

With distribution in more than 90 countries, and claiming “top brand positions” across European markets, Karo’s portfolio spans consumer health categories including skin and intimate health, dietary supplements, digestive health and foot health

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

C&D Taps Hand Sanitizer Category With Touchland

 

Deal totaling as much as $880m extends C&D into additional product category with a brand it says is the fastest growing in the US hand sanitizer category and No. 2 brand in the category overall.

Venture Life Focuses On CHC As It Offloads CDMO

 
• By 

UK-based Venture Life is divesting its CDMO business and some non-core products to focus its attention on growing its consumer health operation.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Australia’s Wellnex Life Poised To Enter UK’s CHC Market

 
• By 

Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.

More from Wellness

Kennedy’s Balancing Act: Push MAHA, Trim Regs

 

Same-day announcements of RFIs from HHS secretary cover nutrient review process for infant formula and Kennedy’s “10-to-1 deregulatory policy” as part of president’s “broader federal effort to reduce regulatory burdens and increase transparency.”

Haleon Utilizing AI To Develop Natural CHC Products

 
• By 

Haleon is partnering with San Francisco's Brightseed to utilize its AI technology to identify bioactive compounds in plants for use in consumer health products.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By 

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.